FDA Approves IV Secukinumab On 10/6/23, Novartis announced the FDA approved an IV formulation of secukinumab (Cosentyx
Tweet Content
FDA Approves IV Secukinumab
On 10/6/23, Novartis announced the FDA approved an IV formulation of secukinumab (Cosentyx) for use in treating adults with PsA, ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)
https://t.co/zv7b98ZUjS https://t.co/1rXjYIbLpw
Show on Archive Page
On
Display in Search Results
On
PDQ
Off